Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients

Intra-abdominal fat area is a predictor for new onset of individual components of metabolic syndrome: MEtabolic syndRome and abdominaL ObesiTy (MERLOT study)

(2012) Yoko M. NAKAO et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

The Evaluation of Body Composition: A Useful Tool for Clinical Practice

(2011) Ronan Thibault et al.   ANNALS OF NUTRITION AND METABOLISM

An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity

(2010) Carla M. M. Prado et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats

(2009) Nobuyuki Sugioka et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

(2009) C. M.M. Prado et al.   CLINICAL CANCER RESEARCH

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

(2008) Patrick A. Thompson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study

(2008) Carla MM Prado et al.   LANCET ONCOLOGY